GILD: A Big Biotech on the Verge of an Upgrade

Gilead has a short but solid dividend-paying track record and a nice, low payout ratio. The only knock on the stock from a dividend safety standpoint has been falling cash flow. That puts the stock at moderate risk for a dividend cut.